| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Transplantation | 11 | 2023 | 839 | 1.270 |
Why?
|
| Kidney Failure, Chronic | 7 | 2023 | 365 | 1.240 |
Why?
|
| Diabetes Mellitus, Type 2 | 9 | 2021 | 1085 | 1.200 |
Why?
|
| Quality Improvement | 9 | 2022 | 413 | 1.190 |
Why?
|
| Hospitalization | 12 | 2023 | 977 | 1.180 |
Why?
|
| Health Care Costs | 14 | 2021 | 346 | 1.120 |
Why?
|
| Primary Health Care | 11 | 2023 | 702 | 1.120 |
Why?
|
| Medication Adherence | 5 | 2012 | 335 | 1.110 |
Why?
|
| Length of Stay | 8 | 2023 | 780 | 1.040 |
Why?
|
| Emergency Service, Hospital | 7 | 2023 | 711 | 0.970 |
Why?
|
| Retrospective Studies | 44 | 2023 | 7268 | 0.910 |
Why?
|
| Hypoglycemic Agents | 6 | 2012 | 361 | 0.900 |
Why?
|
| Anti-Bacterial Agents | 9 | 2015 | 1026 | 0.880 |
Why?
|
| Analgesics, Opioid | 9 | 2022 | 498 | 0.850 |
Why?
|
| Humans | 124 | 2023 | 68549 | 0.790 |
Why?
|
| Medical Record Linkage | 3 | 2016 | 42 | 0.780 |
Why?
|
| Cost of Illness | 6 | 2021 | 204 | 0.780 |
Why?
|
| Inpatients | 3 | 2020 | 208 | 0.750 |
Why?
|
| Middle Aged | 58 | 2022 | 21119 | 0.750 |
Why?
|
| Prescription Drug Monitoring Programs | 4 | 2021 | 34 | 0.730 |
Why?
|
| Adult | 54 | 2023 | 21379 | 0.720 |
Why?
|
| Medical Overuse | 2 | 2016 | 28 | 0.680 |
Why?
|
| South Carolina | 21 | 2021 | 2752 | 0.680 |
Why?
|
| Health Information Exchange | 2 | 2016 | 37 | 0.670 |
Why?
|
| Data Collection | 2 | 2012 | 420 | 0.660 |
Why?
|
| Female | 71 | 2022 | 38021 | 0.660 |
Why?
|
| Tissue and Organ Procurement | 2 | 2021 | 164 | 0.650 |
Why?
|
| Male | 64 | 2022 | 37283 | 0.640 |
Why?
|
| Databases, Factual | 3 | 2020 | 621 | 0.640 |
Why?
|
| Staphylococcal Infections | 2 | 2011 | 156 | 0.630 |
Why?
|
| Hospitals | 5 | 2023 | 265 | 0.630 |
Why?
|
| Hospital Mortality | 3 | 2020 | 384 | 0.620 |
Why?
|
| Aged | 40 | 2022 | 14842 | 0.610 |
Why?
|
| Hospital Costs | 10 | 2014 | 117 | 0.610 |
Why?
|
| Gram-Negative Bacteria | 2 | 2009 | 55 | 0.610 |
Why?
|
| Angioplasty, Balloon, Coronary | 12 | 2005 | 178 | 0.600 |
Why?
|
| Abdominal Injuries | 4 | 2018 | 60 | 0.600 |
Why?
|
| Wounds, Nonpenetrating | 4 | 2018 | 131 | 0.570 |
Why?
|
| Coronary Artery Bypass | 9 | 2005 | 218 | 0.570 |
Why?
|
| Veterans | 7 | 2012 | 904 | 0.560 |
Why?
|
| Patient Discharge | 5 | 2022 | 294 | 0.550 |
Why?
|
| Healthcare Disparities | 6 | 2023 | 378 | 0.530 |
Why?
|
| Sphincter of Oddi Dysfunction | 5 | 2014 | 48 | 0.520 |
Why?
|
| United States | 32 | 2022 | 7338 | 0.510 |
Why?
|
| Risk Adjustment | 1 | 2015 | 49 | 0.490 |
Why?
|
| Myocardial Infarction | 2 | 2020 | 807 | 0.490 |
Why?
|
| Cross Infection | 4 | 2011 | 195 | 0.490 |
Why?
|
| Graft Survival | 6 | 2019 | 465 | 0.480 |
Why?
|
| Drug Resistance, Bacterial | 3 | 2010 | 98 | 0.470 |
Why?
|
| Electronic Health Records | 6 | 2020 | 374 | 0.430 |
Why?
|
| Liver Function Tests | 5 | 2019 | 114 | 0.430 |
Why?
|
| Liver Diseases | 3 | 2019 | 193 | 0.420 |
Why?
|
| Abdominal Pain | 4 | 2014 | 97 | 0.420 |
Why?
|
| Hospital-Physician Relations | 1 | 2012 | 5 | 0.410 |
Why?
|
| Biometry | 1 | 2012 | 72 | 0.410 |
Why?
|
| Delirium | 2 | 2023 | 45 | 0.410 |
Why?
|
| Stroke | 7 | 2017 | 2162 | 0.410 |
Why?
|
| Liver Cirrhosis | 4 | 2023 | 301 | 0.400 |
Why?
|
| Adolescent | 22 | 2022 | 8904 | 0.400 |
Why?
|
| Blood Glucose | 3 | 2012 | 631 | 0.400 |
Why?
|
| Hospital Information Systems | 1 | 2012 | 44 | 0.390 |
Why?
|
| Vancomycin | 1 | 2011 | 60 | 0.390 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2023 | 87 | 0.380 |
Why?
|
| Coronary Disease | 10 | 2000 | 358 | 0.380 |
Why?
|
| Data Interpretation, Statistical | 1 | 2012 | 329 | 0.370 |
Why?
|
| Methicillin Resistance | 2 | 2008 | 45 | 0.370 |
Why?
|
| Patient Acceptance of Health Care | 5 | 2019 | 467 | 0.370 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2011 | 92 | 0.370 |
Why?
|
| Health Resources | 4 | 2017 | 76 | 0.330 |
Why?
|
| Communication | 1 | 2012 | 329 | 0.330 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2009 | 62 | 0.330 |
Why?
|
| Cost Savings | 5 | 2021 | 110 | 0.330 |
Why?
|
| Hepatitis C | 2 | 2020 | 114 | 0.320 |
Why?
|
| Staphylococcus aureus | 2 | 2008 | 175 | 0.320 |
Why?
|
| Kidney Diseases | 1 | 2011 | 307 | 0.320 |
Why?
|
| Health Expenditures | 4 | 2020 | 168 | 0.320 |
Why?
|
| Aged, 80 and over | 13 | 2021 | 4843 | 0.320 |
Why?
|
| Child, Preschool | 9 | 2021 | 3187 | 0.320 |
Why?
|
| Young Adult | 14 | 2022 | 5710 | 0.320 |
Why?
|
| Internal Medicine | 4 | 2018 | 118 | 0.310 |
Why?
|
| Endovascular Procedures | 3 | 2017 | 366 | 0.310 |
Why?
|
| Vancomycin Resistance | 1 | 2008 | 18 | 0.310 |
Why?
|
| Enterococcus | 1 | 2008 | 29 | 0.310 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2008 | 35 | 0.310 |
Why?
|
| Multivariate Analysis | 11 | 2018 | 1046 | 0.310 |
Why?
|
| Child | 12 | 2022 | 6401 | 0.300 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 3 | 2015 | 47 | 0.300 |
Why?
|
| Pseudomonas aeruginosa | 4 | 2011 | 133 | 0.300 |
Why?
|
| Health Services | 1 | 2008 | 87 | 0.300 |
Why?
|
| Postoperative Complications | 4 | 2020 | 1615 | 0.290 |
Why?
|
| Referral and Consultation | 4 | 2020 | 383 | 0.290 |
Why?
|
| Cohort Studies | 10 | 2019 | 2356 | 0.290 |
Why?
|
| Treatment Outcome | 16 | 2022 | 7028 | 0.280 |
Why?
|
| Tissue Plasminogen Activator | 3 | 2017 | 296 | 0.280 |
Why?
|
| Formularies as Topic | 1 | 2006 | 5 | 0.280 |
Why?
|
| Methicillin | 1 | 2006 | 11 | 0.280 |
Why?
|
| Decision Support Techniques | 5 | 2018 | 191 | 0.280 |
Why?
|
| Patient-Centered Care | 2 | 2018 | 106 | 0.280 |
Why?
|
| Sphincterotomy, Endoscopic | 4 | 2014 | 79 | 0.270 |
Why?
|
| Prospective Studies | 13 | 2021 | 3703 | 0.260 |
Why?
|
| Cholecystectomy | 3 | 2014 | 79 | 0.260 |
Why?
|
| Metabolic Syndrome | 2 | 2021 | 191 | 0.260 |
Why?
|
| Parkinson Disease | 1 | 2008 | 272 | 0.250 |
Why?
|
| Infant | 6 | 2021 | 2891 | 0.250 |
Why?
|
| Peripheral Arterial Disease | 2 | 2017 | 83 | 0.250 |
Why?
|
| Linear Models | 4 | 2020 | 521 | 0.250 |
Why?
|
| Risk Factors | 11 | 2022 | 5720 | 0.250 |
Why?
|
| Vascular Surgical Procedures | 2 | 2017 | 168 | 0.250 |
Why?
|
| Telephone | 3 | 2010 | 160 | 0.240 |
Why?
|
| Delivery of Health Care | 2 | 2020 | 445 | 0.240 |
Why?
|
| Insulin | 3 | 2012 | 617 | 0.230 |
Why?
|
| Thrombolytic Therapy | 2 | 2017 | 233 | 0.230 |
Why?
|
| Time Factors | 13 | 2019 | 4655 | 0.230 |
Why?
|
| Incidence | 6 | 2022 | 1582 | 0.230 |
Why?
|
| Medicare | 4 | 2021 | 316 | 0.220 |
Why?
|
| Follow-Up Studies | 8 | 2019 | 3256 | 0.220 |
Why?
|
| Drug Prescriptions | 2 | 2021 | 135 | 0.220 |
Why?
|
| Graft Rejection | 4 | 2019 | 458 | 0.220 |
Why?
|
| Patient Transfer | 2 | 2023 | 86 | 0.220 |
Why?
|
| Trauma Centers | 3 | 2018 | 197 | 0.220 |
Why?
|
| Drug Utilization | 4 | 2012 | 119 | 0.210 |
Why?
|
| Models, Statistical | 2 | 2019 | 448 | 0.210 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2020 | 105 | 0.210 |
Why?
|
| Practice Patterns, Physicians' | 6 | 2022 | 503 | 0.210 |
Why?
|
| Subacute Care | 1 | 2022 | 11 | 0.210 |
Why?
|
| Transaminases | 1 | 2022 | 21 | 0.200 |
Why?
|
| Telemedicine | 3 | 2021 | 699 | 0.200 |
Why?
|
| Gonorrhea | 1 | 2022 | 50 | 0.200 |
Why?
|
| Severity of Illness Index | 4 | 2023 | 1851 | 0.200 |
Why?
|
| Ciprofloxacin | 2 | 2015 | 30 | 0.200 |
Why?
|
| Reimbursement Mechanisms | 1 | 2021 | 37 | 0.200 |
Why?
|
| Cause of Death | 2 | 2020 | 241 | 0.190 |
Why?
|
| Patient Admission | 2 | 2016 | 99 | 0.190 |
Why?
|
| Age Factors | 7 | 2018 | 1860 | 0.190 |
Why?
|
| Cost-Benefit Analysis | 6 | 2017 | 503 | 0.190 |
Why?
|
| Policy | 1 | 2021 | 58 | 0.190 |
Why?
|
| Regional Medical Programs | 1 | 2020 | 22 | 0.190 |
Why?
|
| Hematinics | 1 | 2021 | 52 | 0.190 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 5 | 2014 | 348 | 0.190 |
Why?
|
| Administration, Oral | 2 | 2012 | 411 | 0.190 |
Why?
|
| Intersectoral Collaboration | 1 | 2020 | 27 | 0.190 |
Why?
|
| Longitudinal Studies | 4 | 2022 | 1054 | 0.190 |
Why?
|
| Breast Neoplasms | 4 | 2022 | 1533 | 0.180 |
Why?
|
| Hospital Administration | 1 | 2020 | 43 | 0.180 |
Why?
|
| Anemia | 1 | 2021 | 104 | 0.180 |
Why?
|
| Glomerular Filtration Rate | 2 | 2019 | 274 | 0.180 |
Why?
|
| Acute Disease | 2 | 2020 | 658 | 0.180 |
Why?
|
| Comorbidity | 5 | 2016 | 1425 | 0.180 |
Why?
|
| Vulnerable Populations | 1 | 2021 | 84 | 0.180 |
Why?
|
| Pseudomonas Infections | 3 | 2011 | 83 | 0.180 |
Why?
|
| Tonsillectomy | 1 | 2021 | 69 | 0.180 |
Why?
|
| Infant, Newborn | 6 | 2021 | 2455 | 0.180 |
Why?
|
| Patient Participation | 1 | 2021 | 145 | 0.180 |
Why?
|
| Tacrolimus | 2 | 2018 | 127 | 0.180 |
Why?
|
| Efficiency | 1 | 2020 | 49 | 0.170 |
Why?
|
| Patient Selection | 3 | 2021 | 592 | 0.170 |
Why?
|
| Morbidity | 1 | 2020 | 130 | 0.170 |
Why?
|
| Proportional Hazards Models | 6 | 2019 | 791 | 0.170 |
Why?
|
| Hepatitis C Antibodies | 1 | 2019 | 19 | 0.170 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2022 | 285 | 0.170 |
Why?
|
| Survival Rate | 3 | 2018 | 1055 | 0.170 |
Why?
|
| Health Policy | 1 | 2021 | 221 | 0.170 |
Why?
|
| Escherichia coli | 2 | 2015 | 368 | 0.170 |
Why?
|
| Insurance, Health | 2 | 2020 | 200 | 0.170 |
Why?
|
| Labor Presentation | 1 | 1998 | 8 | 0.160 |
Why?
|
| Physicians, Primary Care | 1 | 2019 | 46 | 0.160 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2011 | 226 | 0.160 |
Why?
|
| Internship and Residency | 2 | 2015 | 596 | 0.160 |
Why?
|
| Twins | 1 | 1998 | 42 | 0.160 |
Why?
|
| Hospitals, University | 3 | 2016 | 169 | 0.160 |
Why?
|
| Delivery, Obstetric | 1 | 1998 | 58 | 0.160 |
Why?
|
| Fluoroquinolones | 2 | 2011 | 49 | 0.160 |
Why?
|
| Liver Neoplasms | 1 | 2022 | 334 | 0.160 |
Why?
|
| Chronic Disease | 2 | 2016 | 1329 | 0.160 |
Why?
|
| Opioid-Related Disorders | 1 | 2022 | 298 | 0.150 |
Why?
|
| Medicaid | 4 | 2012 | 301 | 0.150 |
Why?
|
| Colon | 1 | 2018 | 168 | 0.150 |
Why?
|
| Transplant Recipients | 1 | 2018 | 109 | 0.150 |
Why?
|
| Outpatient Clinics, Hospital | 2 | 1996 | 69 | 0.150 |
Why?
|
| Immunosuppressive Agents | 2 | 2018 | 514 | 0.150 |
Why?
|
| Liver | 2 | 2021 | 1118 | 0.150 |
Why?
|
| End Stage Liver Disease | 1 | 2018 | 60 | 0.150 |
Why?
|
| Anti-Infective Agents | 2 | 2011 | 166 | 0.140 |
Why?
|
| Continuity of Patient Care | 1 | 2018 | 170 | 0.140 |
Why?
|
| Pain, Postoperative | 2 | 2022 | 214 | 0.140 |
Why?
|
| Comprehensive Health Care | 1 | 2016 | 26 | 0.140 |
Why?
|
| Aspartate Aminotransferases | 3 | 2023 | 87 | 0.140 |
Why?
|
| Renal Insufficiency | 1 | 2017 | 121 | 0.140 |
Why?
|
| Aftercare | 2 | 2021 | 114 | 0.140 |
Why?
|
| Disability Evaluation | 3 | 2017 | 298 | 0.140 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1996 | 121 | 0.130 |
Why?
|
| Age Distribution | 2 | 2015 | 319 | 0.130 |
Why?
|
| Quality Indicators, Health Care | 1 | 2017 | 136 | 0.130 |
Why?
|
| Academic Medical Centers | 2 | 2016 | 281 | 0.130 |
Why?
|
| Fibrinolytic Agents | 2 | 2017 | 377 | 0.130 |
Why?
|
| Popliteal Artery | 1 | 2015 | 40 | 0.130 |
Why?
|
| Ultrasonography | 1 | 2017 | 453 | 0.130 |
Why?
|
| Escherichia coli Infections | 1 | 2015 | 47 | 0.130 |
Why?
|
| Advance Directives | 1 | 2015 | 22 | 0.130 |
Why?
|
| Patients | 1 | 1995 | 69 | 0.130 |
Why?
|
| Marital Status | 1 | 2015 | 65 | 0.120 |
Why?
|
| Poverty | 2 | 2015 | 218 | 0.120 |
Why?
|
| Emergency Medical Services | 1 | 2017 | 225 | 0.120 |
Why?
|
| Urinary Tract Infections | 1 | 2015 | 71 | 0.120 |
Why?
|
| Economics, Hospital | 1 | 1994 | 15 | 0.120 |
Why?
|
| Feedback, Psychological | 1 | 2014 | 17 | 0.120 |
Why?
|
| Liver Transplantation | 1 | 2018 | 400 | 0.120 |
Why?
|
| Sex Distribution | 1 | 2015 | 272 | 0.120 |
Why?
|
| Heart Diseases | 1 | 1997 | 276 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2010 | 929 | 0.120 |
Why?
|
| Ischemia | 1 | 2015 | 229 | 0.120 |
Why?
|
| Costs and Cost Analysis | 6 | 2014 | 193 | 0.120 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2018 | 2324 | 0.120 |
Why?
|
| Lower Extremity | 1 | 2015 | 153 | 0.120 |
Why?
|
| Brain Ischemia | 2 | 2017 | 665 | 0.120 |
Why?
|
| Mental Disorders | 2 | 2016 | 659 | 0.120 |
Why?
|
| Health Status Indicators | 2 | 1997 | 117 | 0.120 |
Why?
|
| Aphasia | 2 | 2014 | 119 | 0.110 |
Why?
|
| Anesthesia, General | 1 | 2014 | 86 | 0.110 |
Why?
|
| Models, Theoretical | 2 | 2016 | 384 | 0.110 |
Why?
|
| Lymph Nodes | 2 | 2005 | 258 | 0.110 |
Why?
|
| Regression Analysis | 3 | 2015 | 737 | 0.110 |
Why?
|
| Cardiac Surgical Procedures | 2 | 1999 | 450 | 0.110 |
Why?
|
| Canada | 2 | 2017 | 266 | 0.110 |
Why?
|
| Cross-Sectional Studies | 4 | 2023 | 2265 | 0.110 |
Why?
|
| Physician-Patient Relations | 1 | 2015 | 261 | 0.110 |
Why?
|
| Predictive Value of Tests | 5 | 2019 | 1465 | 0.110 |
Why?
|
| Risk Assessment | 4 | 2022 | 2004 | 0.110 |
Why?
|
| Hospital Charges | 3 | 2014 | 60 | 0.110 |
Why?
|
| Polypharmacy | 1 | 2012 | 31 | 0.110 |
Why?
|
| Health Personnel | 1 | 1995 | 286 | 0.100 |
Why?
|
| Hospitals, Teaching | 2 | 2016 | 65 | 0.100 |
Why?
|
| Patient Care Team | 1 | 2014 | 311 | 0.100 |
Why?
|
| Pneumococcal Vaccines | 1 | 2012 | 30 | 0.100 |
Why?
|
| Mortality | 1 | 2012 | 162 | 0.100 |
Why?
|
| Pneumococcal Infections | 1 | 2012 | 30 | 0.100 |
Why?
|
| Outpatients | 1 | 2012 | 127 | 0.100 |
Why?
|
| Accidental Falls | 1 | 2012 | 84 | 0.100 |
Why?
|
| Influenza Vaccines | 1 | 2012 | 56 | 0.100 |
Why?
|
| Precision Medicine | 1 | 2012 | 111 | 0.100 |
Why?
|
| Random Allocation | 1 | 2012 | 442 | 0.100 |
Why?
|
| Renal Dialysis | 2 | 2023 | 174 | 0.100 |
Why?
|
| Influenza, Human | 1 | 2012 | 79 | 0.100 |
Why?
|
| Education, Medical, Continuing | 1 | 2012 | 136 | 0.100 |
Why?
|
| Psychiatry | 1 | 2012 | 112 | 0.100 |
Why?
|
| Urban Population | 2 | 2011 | 254 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 536 | 0.100 |
Why?
|
| Creatinine | 1 | 2011 | 243 | 0.090 |
Why?
|
| Waiting Lists | 2 | 2021 | 104 | 0.090 |
Why?
|
| Evidence-Based Medicine | 2 | 2012 | 438 | 0.090 |
Why?
|
| Pediatrics | 1 | 2014 | 341 | 0.090 |
Why?
|
| Schizophrenia | 1 | 2012 | 206 | 0.090 |
Why?
|
| Fibrosis | 2 | 2023 | 371 | 0.090 |
Why?
|
| Reproducibility of Results | 3 | 2018 | 2077 | 0.090 |
Why?
|
| Research Design | 5 | 2010 | 729 | 0.090 |
Why?
|
| Deglutition Disorders | 1 | 2014 | 297 | 0.090 |
Why?
|
| Enterobacteriaceae | 1 | 2010 | 29 | 0.090 |
Why?
|
| Colonic Neoplasms | 1 | 2012 | 299 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2012 | 444 | 0.090 |
Why?
|
| Relative Value Scales | 3 | 2000 | 8 | 0.090 |
Why?
|
| Sensitivity and Specificity | 5 | 2018 | 1753 | 0.090 |
Why?
|
| Breech Presentation | 2 | 2000 | 11 | 0.090 |
Why?
|
| Health Care Sector | 2 | 1999 | 26 | 0.090 |
Why?
|
| Alanine Transaminase | 2 | 2021 | 137 | 0.090 |
Why?
|
| Models, Econometric | 3 | 2005 | 26 | 0.080 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2009 | 14 | 0.080 |
Why?
|
| Telefacsimile | 1 | 2009 | 6 | 0.080 |
Why?
|
| Drug Therapy, Combination | 1 | 2011 | 648 | 0.080 |
Why?
|
| Pharmacies | 1 | 2009 | 18 | 0.080 |
Why?
|
| Videoconferencing | 1 | 2009 | 43 | 0.080 |
Why?
|
| Version, Fetal | 2 | 2000 | 8 | 0.080 |
Why?
|
| Hypertension | 1 | 2018 | 1533 | 0.080 |
Why?
|
| Quality of Life | 4 | 2008 | 1515 | 0.080 |
Why?
|
| Reminder Systems | 1 | 2009 | 39 | 0.080 |
Why?
|
| Odds Ratio | 3 | 2017 | 880 | 0.080 |
Why?
|
| Disease Outbreaks | 1 | 2009 | 83 | 0.080 |
Why?
|
| Rural Health Services | 1 | 2009 | 101 | 0.080 |
Why?
|
| Demography | 2 | 2021 | 279 | 0.080 |
Why?
|
| Health Services Accessibility | 3 | 2009 | 581 | 0.080 |
Why?
|
| Infection Control | 1 | 2009 | 101 | 0.080 |
Why?
|
| Prevalence | 3 | 2018 | 1609 | 0.080 |
Why?
|
| Counseling | 1 | 2010 | 279 | 0.080 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2012 | 766 | 0.080 |
Why?
|
| Manometry | 3 | 2014 | 276 | 0.080 |
Why?
|
| Rural Population | 1 | 2011 | 397 | 0.070 |
Why?
|
| Pancreatic Fistula | 1 | 2007 | 23 | 0.070 |
Why?
|
| Injury Severity Score | 2 | 2018 | 204 | 0.070 |
Why?
|
| Socioeconomic Factors | 4 | 2012 | 955 | 0.070 |
Why?
|
| SEER Program | 2 | 2021 | 150 | 0.070 |
Why?
|
| Analysis of Variance | 1 | 2009 | 1040 | 0.070 |
Why?
|
| Patient Education as Topic | 1 | 2010 | 424 | 0.070 |
Why?
|
| Interviews as Topic | 1 | 2008 | 392 | 0.070 |
Why?
|
| Prognosis | 4 | 2019 | 2093 | 0.070 |
Why?
|
| Psychotherapy | 1 | 2009 | 253 | 0.070 |
Why?
|
| Ofloxacin | 1 | 2006 | 15 | 0.070 |
Why?
|
| Patient Credit and Collection | 1 | 2006 | 7 | 0.070 |
Why?
|
| Behavior Therapy | 1 | 2009 | 297 | 0.070 |
Why?
|
| Pancreatectomy | 1 | 2007 | 129 | 0.070 |
Why?
|
| Levofloxacin | 1 | 2006 | 23 | 0.070 |
Why?
|
| Health Behavior | 1 | 2010 | 458 | 0.070 |
Why?
|
| Health Services Research | 2 | 2018 | 209 | 0.070 |
Why?
|
| Pancreatitis, Chronic | 1 | 2007 | 168 | 0.060 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2005 | 53 | 0.060 |
Why?
|
| Pregnancy | 4 | 2016 | 2334 | 0.060 |
Why?
|
| Chi-Square Distribution | 2 | 2017 | 546 | 0.060 |
Why?
|
| Depressive Disorder, Major | 1 | 2009 | 438 | 0.060 |
Why?
|
| Pancreatitis | 2 | 2014 | 279 | 0.060 |
Why?
|
| Colonography, Computed Tomographic | 1 | 2004 | 23 | 0.060 |
Why?
|
| Managed Care Programs | 3 | 1999 | 45 | 0.060 |
Why?
|
| Stroke Rehabilitation | 1 | 2008 | 335 | 0.060 |
Why?
|
| Fees, Medical | 2 | 2000 | 9 | 0.060 |
Why?
|
| Stents | 2 | 1998 | 657 | 0.060 |
Why?
|
| Colonoscopy | 1 | 2004 | 156 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 1 | 2004 | 369 | 0.050 |
Why?
|
| Registries | 2 | 2017 | 730 | 0.050 |
Why?
|
| Infusions, Intravenous | 2 | 2017 | 334 | 0.050 |
Why?
|
| Cystic Fibrosis | 1 | 2006 | 283 | 0.050 |
Why?
|
| Physicians | 2 | 1996 | 324 | 0.050 |
Why?
|
| Appendectomy | 1 | 2022 | 47 | 0.050 |
Why?
|
| Cardiovascular Diseases | 2 | 1999 | 938 | 0.050 |
Why?
|
| Georgia | 3 | 2000 | 161 | 0.050 |
Why?
|
| Residence Characteristics | 2 | 2014 | 252 | 0.050 |
Why?
|
| Preventive Health Services | 1 | 2022 | 86 | 0.050 |
Why?
|
| Controlled Substances | 1 | 2021 | 5 | 0.050 |
Why?
|
| Ecosystem | 1 | 2021 | 54 | 0.050 |
Why?
|
| Forecasting | 2 | 2019 | 277 | 0.050 |
Why?
|
| Stakeholder Participation | 1 | 2020 | 17 | 0.050 |
Why?
|
| Sustained Virologic Response | 1 | 2020 | 11 | 0.050 |
Why?
|
| Cesarean Section | 2 | 1998 | 101 | 0.050 |
Why?
|
| Prescription Drug Misuse | 1 | 2021 | 35 | 0.050 |
Why?
|
| Self Efficacy | 1 | 2021 | 199 | 0.050 |
Why?
|
| Obstetrics and Gynecology Department, Hospital | 1 | 2000 | 11 | 0.050 |
Why?
|
| Specialization | 1 | 2020 | 66 | 0.050 |
Why?
|
| Pharmacists | 1 | 2021 | 125 | 0.050 |
Why?
|
| Insurance Carriers | 1 | 2020 | 9 | 0.040 |
Why?
|
| Ambulatory Care | 1 | 2022 | 339 | 0.040 |
Why?
|
| Monitoring, Physiologic | 1 | 2021 | 219 | 0.040 |
Why?
|
| Biopsy | 1 | 2021 | 539 | 0.040 |
Why?
|
| Cholangiography | 1 | 1999 | 55 | 0.040 |
Why?
|
| Kidney Function Tests | 1 | 2019 | 114 | 0.040 |
Why?
|
| Cholelithiasis | 1 | 1999 | 66 | 0.040 |
Why?
|
| Colorectal Neoplasms | 1 | 2004 | 560 | 0.040 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 1999 | 59 | 0.040 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2009 | 1506 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2019 | 242 | 0.040 |
Why?
|
| Diseases in Twins | 1 | 1998 | 31 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2020 | 211 | 0.040 |
Why?
|
| Sphincter of Oddi | 1 | 1998 | 51 | 0.040 |
Why?
|
| Intensive Care, Neonatal | 1 | 1998 | 38 | 0.040 |
Why?
|
| Alkaline Phosphatase | 1 | 2018 | 71 | 0.040 |
Why?
|
| Models, Economic | 1 | 2018 | 69 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2018 | 50 | 0.040 |
Why?
|
| Pregnancy Outcome | 1 | 1998 | 157 | 0.040 |
Why?
|
| Technology Assessment, Biomedical | 1 | 1997 | 24 | 0.040 |
Why?
|
| Endosonography | 1 | 1999 | 177 | 0.040 |
Why?
|
| Nursing Research | 1 | 1998 | 40 | 0.040 |
Why?
|
| Laparotomy | 1 | 2017 | 65 | 0.040 |
Why?
|
| False Negative Reactions | 1 | 2017 | 63 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2018 | 239 | 0.040 |
Why?
|
| Fee-for-Service Plans | 1 | 1997 | 24 | 0.040 |
Why?
|
| Atherectomy, Coronary | 1 | 1997 | 5 | 0.040 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 1997 | 47 | 0.040 |
Why?
|
| Europe | 1 | 2017 | 196 | 0.040 |
Why?
|
| Lung Diseases | 1 | 1998 | 175 | 0.040 |
Why?
|
| Angiography | 1 | 2017 | 194 | 0.040 |
Why?
|
| Reoperation | 1 | 2018 | 467 | 0.040 |
Why?
|
| Organizational Innovation | 1 | 2016 | 55 | 0.040 |
Why?
|
| Cardiac Catheterization | 2 | 1996 | 419 | 0.040 |
Why?
|
| Patient Identification Systems | 1 | 2016 | 18 | 0.030 |
Why?
|
| Fee Schedules | 1 | 1996 | 2 | 0.030 |
Why?
|
| Medicare Part B | 1 | 1996 | 3 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 567 | 0.030 |
Why?
|
| Australia | 1 | 2017 | 235 | 0.030 |
Why?
|
| Hospitals, Public | 1 | 2016 | 22 | 0.030 |
Why?
|
| Coronary Angiography | 3 | 1996 | 866 | 0.030 |
Why?
|
| International Classification of Diseases | 1 | 2016 | 85 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2018 | 402 | 0.030 |
Why?
|
| Equipment and Supplies | 1 | 1995 | 18 | 0.030 |
Why?
|
| Limb Salvage | 1 | 2015 | 39 | 0.030 |
Why?
|
| Ultrasonography, Interventional | 1 | 1996 | 119 | 0.030 |
Why?
|
| Embolization, Therapeutic | 1 | 2017 | 150 | 0.030 |
Why?
|
| Cardiology | 1 | 1997 | 140 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2010 | 1341 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2018 | 326 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 349 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 951 | 0.030 |
Why?
|
| Dysarthria | 1 | 2014 | 9 | 0.030 |
Why?
|
| Economics, Medical | 1 | 1994 | 8 | 0.030 |
Why?
|
| Value of Life | 1 | 1994 | 14 | 0.030 |
Why?
|
| Catheterization | 1 | 1995 | 209 | 0.030 |
Why?
|
| Long-Term Care | 1 | 2014 | 53 | 0.030 |
Why?
|
| Urban Health | 1 | 2014 | 49 | 0.030 |
Why?
|
| Narcotics | 1 | 2014 | 65 | 0.030 |
Why?
|
| Rural Health | 1 | 2014 | 66 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2016 | 267 | 0.030 |
Why?
|
| Surveys and Questionnaires | 2 | 2010 | 2798 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2014 | 238 | 0.030 |
Why?
|
| Pregnancy Complications | 1 | 2016 | 286 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2016 | 442 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2005 | 710 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2015 | 254 | 0.030 |
Why?
|
| Education, Medical, Graduate | 1 | 2015 | 214 | 0.030 |
Why?
|
| Neoplasm Staging | 2 | 2005 | 799 | 0.030 |
Why?
|
| Survivors | 1 | 2014 | 254 | 0.030 |
Why?
|
| Logistic Models | 1 | 2015 | 1419 | 0.020 |
Why?
|
| Nurse Practitioners | 1 | 2012 | 90 | 0.020 |
Why?
|
| Social Class | 2 | 2006 | 127 | 0.020 |
Why?
|
| Penicillanic Acid | 1 | 2011 | 3 | 0.020 |
Why?
|
| Piperacillin | 1 | 2011 | 6 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2014 | 782 | 0.020 |
Why?
|
| Health Status | 1 | 2014 | 429 | 0.020 |
Why?
|
| Tobramycin | 1 | 2011 | 38 | 0.020 |
Why?
|
| Cephalosporins | 1 | 2011 | 59 | 0.020 |
Why?
|
| Risk | 1 | 2012 | 563 | 0.020 |
Why?
|
| Curriculum | 1 | 2015 | 575 | 0.020 |
Why?
|
| Anxiety | 1 | 2014 | 422 | 0.020 |
Why?
|
| Sex Factors | 1 | 2014 | 1265 | 0.020 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2010 | 25 | 0.020 |
Why?
|
| Pamphlets | 1 | 2010 | 27 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 1993 | 378 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2010 | 186 | 0.020 |
Why?
|
| Mass Screening | 1 | 1996 | 838 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2014 | 1738 | 0.020 |
Why?
|
| Algorithms | 1 | 2015 | 1195 | 0.020 |
Why?
|
| Hawaii | 1 | 2009 | 24 | 0.020 |
Why?
|
| Hand Disinfection | 1 | 2009 | 9 | 0.020 |
Why?
|
| Sanitation | 1 | 2009 | 5 | 0.020 |
Why?
|
| Clinical Pharmacy Information Systems | 1 | 2009 | 8 | 0.020 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2009 | 12 | 0.020 |
Why?
|
| Patient Isolation | 1 | 2009 | 35 | 0.020 |
Why?
|
| Bacterial Toxins | 1 | 2009 | 50 | 0.020 |
Why?
|
| Directive Counseling | 1 | 2009 | 23 | 0.020 |
Why?
|
| Pain Management | 1 | 2010 | 186 | 0.020 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2008 | 27 | 0.020 |
Why?
|
| Survival Analysis | 2 | 2004 | 714 | 0.020 |
Why?
|
| Mental Health Services | 1 | 2009 | 199 | 0.020 |
Why?
|
| Pain | 1 | 2010 | 472 | 0.020 |
Why?
|
| Depression | 1 | 2014 | 942 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 2004 | 1549 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2009 | 502 | 0.020 |
Why?
|
| Diagnosis-Related Groups | 1 | 2006 | 28 | 0.020 |
Why?
|
| Social Justice | 1 | 2006 | 32 | 0.020 |
Why?
|
| Statistical Distributions | 1 | 2005 | 8 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 2 | 1996 | 219 | 0.020 |
Why?
|
| Motivation | 1 | 2010 | 561 | 0.020 |
Why?
|
| Selection Bias | 1 | 2005 | 23 | 0.020 |
Why?
|
| Benchmarking | 1 | 2005 | 91 | 0.020 |
Why?
|
| Bone Marrow | 1 | 2005 | 168 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2005 | 274 | 0.020 |
Why?
|
| Axilla | 1 | 2004 | 36 | 0.020 |
Why?
|
| Biomarkers | 1 | 2010 | 1593 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2005 | 306 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 2004 | 76 | 0.010 |
Why?
|
| Lymph Node Excision | 1 | 2004 | 91 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 191 | 0.010 |
Why?
|
| Reference Values | 1 | 2004 | 579 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 1174 | 0.010 |
Why?
|
| Hospitals, Urban | 1 | 2000 | 46 | 0.010 |
Why?
|
| Angina, Unstable | 1 | 2000 | 50 | 0.010 |
Why?
|
| Angina Pectoris | 1 | 2000 | 61 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2000 | 306 | 0.010 |
Why?
|
| Medical Laboratory Science | 1 | 1999 | 8 | 0.010 |
Why?
|
| Physician's Role | 1 | 2000 | 116 | 0.010 |
Why?
|
| Unnecessary Procedures | 1 | 1999 | 49 | 0.010 |
Why?
|
| Cardiovascular Agents | 1 | 1999 | 82 | 0.010 |
Why?
|
| Intraoperative Care | 1 | 1999 | 91 | 0.010 |
Why?
|
| Professional Competence | 1 | 1999 | 100 | 0.010 |
Why?
|
| Least-Squares Analysis | 1 | 1997 | 35 | 0.010 |
Why?
|
| Capitation Fee | 1 | 1997 | 4 | 0.010 |
Why?
|
| Cost Control | 1 | 1997 | 34 | 0.010 |
Why?
|
| New Jersey | 1 | 1996 | 8 | 0.010 |
Why?
|
| Medical Staff, Hospital | 1 | 1995 | 44 | 0.010 |
Why?
|
| Chest Pain | 1 | 1995 | 151 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 1999 | 772 | 0.010 |
Why?
|
| Recurrence | 1 | 1997 | 948 | 0.010 |
Why?
|
| Policy Making | 1 | 1994 | 51 | 0.010 |
Why?
|
| Mammography | 1 | 1996 | 310 | 0.010 |
Why?
|
| Clinical Competence | 1 | 1996 | 657 | 0.010 |
Why?
|
| Heart Failure | 1 | 1995 | 1179 | 0.000 |
Why?
|